Stereostactic microwave ablation as an alternative to surgical resection for colorectal cancer liver metastates
Author: Tinguely, Pascale
Date: 2023-06-16
Location: Aulan, Danderyd Hospital, Stockholm, Sweden
Time: 10.00
Department: Inst för kliniska vetenskaper, Danderyds sjukhus / Dept of Clinical Sciences, Danderyd Hospital
View/ Open:
Thesis (12.36Mb)
Abstract
Colorectal cancer (CRC) implies a substantial global burden of disease with a relevant
impact on the general population and on healthcare systems in terms of morbidity,
mortality, quality of life, and costs. A raising CRC incidence emphasises the need to refine
screening and prevention strategies, and design optimal algorithms for treatment
indication and outcome prediction. Around 25% to 30% of patients with CRC develop
colorectal cancer liver metastases (CRLM) at any time point during their disease, with high
variation in the disease presentation, severity, chronology and response to treatment. This
and the increasing quantity and quality of available therapeutic options, enhance the
complexity of defining treatment algorithms and designing feasible studies leading to
meaningful results. Considering the high rate of tumour recurrence after initial CRLM
treatment with curative intent, applying low-morbidity local treatments enhancing the
possibilities of repeat treatments, are gaining importance. As such, thermal ablation (TA)
promises high rates of local tumour control and favourable oncological outcomes
comparable to the gold-standard surgical resection. Nevertheless, results from highquality
prospective comparative studies are missing, hampering the integration of TA as
a valid treatment alternative into current guidelines. The aims of the studies included in
this thesis were to investigate i) non-inferiority in overall survival (OS), and compare
healthcare consumption, costs and treatment-associated morbidity, when treating
patients with potentially resectable CRLM with TA versus resection, while applying highlevel
navigation technology for stereotactic microwave ablation (SMWA), and ii) the
potential of a novel algorithm for computation of 3D quantitative ablation margins (QAM)
to enhance treatment success and predict local tumour control after SMWA.
Study I was a population-based analysis comparing 3-year OS after microwave ablation (MWA) versus resection using data from a nationwide Swedish patient registry. After adjusting for factors known to affect the treatment type and OS (confounding by indication) using propensity score (PS) analysis, 3-year OS probabilities were similar in patients treated with MWA (n = 70) (76%, CI 59% to 86%) versus resection (n = 201) (3- year OS 76%, CI 68% to 83%), with a change in the hazard of death of 1.43 (CI 0.77 to 2.65) induced by the treatment type in a multivariable model.
Studies II, III and IV were analyses or sub-analyses of a prospective, multi-centre cohort study (MAVERRIC study), comparing patients with ≤ 5 CRLM ≤ 3cm in size, qualifying for both SMWA and resection and deliberately treated with SMWA (study group), to a contemporary cohort of patients treated with resection, extracted from a Swedish nationwide patient registry (control group). The primary outcome of 3-year OS after a prospective follow-up of 3 years was analysed in Study IV. PS analyses yielded comparable groups with a balanced distribution of baseline characteristics across the study (n = 98) and control (n = 158) cohorts. Three-year OS was non-inferior after SMWA (78%, CI 68% to 85%) versus resection (76% (CI 69% to 82%), with a hazard ratio (HR) of 1.09 (CI 0.69 to 1.51) for the treatment type (SMWA over resection). In the Swedish subgroup of patients included into the MAVERRIC study, a particular inclusion pattern (patients amenable to both ablation and resection treated with SMWA every even week and with resection every odd week) created a quasi-randomised situation, where healthcare related costs and OS were analysed (Study III). Overall costs (all inpatient hospital admissions, outpatient visits, oncological treatments and radiological imaging) from the time of index treatment indication and two years onwards, were significantly reduced in the SMWA versus resection cohorts. Two-year OS and disease-free survival were similar, while hepatic recurrence-free survival was shorter and hepatic re-treatments more frequent after SMWA. Morbidity and length of hospital stay were significantly reduced, and re-treatment significantly more frequent, after MWA / SMWA versus resection, in Studies I, III and IV.
Study II was a secondary outcome-analysis applying a novel QAM metric on a subgroup of patients treated with SMWA within the MAVERRIC study. 3D-QAM was retrospectively computed to 65 CRLM treated with SMWA, and varying definitions investigated in a multivariable model. 3D-QAM was the most relevant factor affecting the occurrence of local recurrence within one year of treatment.
In conclusion, OS at 3 years may be considered similar after SMWA versus resection in patients with potentially resectable small CRLM, with significantly reduced morbidity, time spent in medical facilities and healthcare related costs. In an ageing and more comorbid population, this supports the role of TA as a valid low-morbidity, tissue-sparing treatment alternative, enhancing options for re-treatments in case of hepatic recurrences. This and the potential of innovative technology to enhance safety, efficacy and reproducibility of results, might aid decision-making when designing individualised treatment algorithms for patients with CRLM.
Study I was a population-based analysis comparing 3-year OS after microwave ablation (MWA) versus resection using data from a nationwide Swedish patient registry. After adjusting for factors known to affect the treatment type and OS (confounding by indication) using propensity score (PS) analysis, 3-year OS probabilities were similar in patients treated with MWA (n = 70) (76%, CI 59% to 86%) versus resection (n = 201) (3- year OS 76%, CI 68% to 83%), with a change in the hazard of death of 1.43 (CI 0.77 to 2.65) induced by the treatment type in a multivariable model.
Studies II, III and IV were analyses or sub-analyses of a prospective, multi-centre cohort study (MAVERRIC study), comparing patients with ≤ 5 CRLM ≤ 3cm in size, qualifying for both SMWA and resection and deliberately treated with SMWA (study group), to a contemporary cohort of patients treated with resection, extracted from a Swedish nationwide patient registry (control group). The primary outcome of 3-year OS after a prospective follow-up of 3 years was analysed in Study IV. PS analyses yielded comparable groups with a balanced distribution of baseline characteristics across the study (n = 98) and control (n = 158) cohorts. Three-year OS was non-inferior after SMWA (78%, CI 68% to 85%) versus resection (76% (CI 69% to 82%), with a hazard ratio (HR) of 1.09 (CI 0.69 to 1.51) for the treatment type (SMWA over resection). In the Swedish subgroup of patients included into the MAVERRIC study, a particular inclusion pattern (patients amenable to both ablation and resection treated with SMWA every even week and with resection every odd week) created a quasi-randomised situation, where healthcare related costs and OS were analysed (Study III). Overall costs (all inpatient hospital admissions, outpatient visits, oncological treatments and radiological imaging) from the time of index treatment indication and two years onwards, were significantly reduced in the SMWA versus resection cohorts. Two-year OS and disease-free survival were similar, while hepatic recurrence-free survival was shorter and hepatic re-treatments more frequent after SMWA. Morbidity and length of hospital stay were significantly reduced, and re-treatment significantly more frequent, after MWA / SMWA versus resection, in Studies I, III and IV.
Study II was a secondary outcome-analysis applying a novel QAM metric on a subgroup of patients treated with SMWA within the MAVERRIC study. 3D-QAM was retrospectively computed to 65 CRLM treated with SMWA, and varying definitions investigated in a multivariable model. 3D-QAM was the most relevant factor affecting the occurrence of local recurrence within one year of treatment.
In conclusion, OS at 3 years may be considered similar after SMWA versus resection in patients with potentially resectable small CRLM, with significantly reduced morbidity, time spent in medical facilities and healthcare related costs. In an ageing and more comorbid population, this supports the role of TA as a valid low-morbidity, tissue-sparing treatment alternative, enhancing options for re-treatments in case of hepatic recurrences. This and the potential of innovative technology to enhance safety, efficacy and reproducibility of results, might aid decision-making when designing individualised treatment algorithms for patients with CRLM.
List of papers:
I. Microwave ablation versus resection for colorectal cancer liver metastases - A propensity score analysis from a population-based nationwide registry. Pascale Tinguely, Gabriella Dal, Matteo Bottai, Henrik Nilsson, Jacob Freedman, Jennie Engstrand. European Journal of Surgical Oncology. 2020;46(3): 476-485.
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. 3D Quantitative Ablation Margins for Prediction of Ablation Site Recurrence After Stereotactic Image-Guided Microwave Ablation of Colorectal Liver Metastases: A Multicenter Study. Simeon J. S. Ruiter / Pascale Tinguely (shared first authorship), Iwan Paolucci, Jennie Engstrand, Daniel Candinas, Stefan Weber, Robbert J. de Haas, Koert P. de Jong, Jacob Freedman. Frontiers in Oncology. 2021 Nov 15;11:757167.
Fulltext (DOI)
Pubmed
View record in Web of Science®
III. Ablation versus resection for resectable colorectal liver metastases - Healthcare-related cost and survival analyses from a quasi-randomised study. Pascale Tinguely, Gustaf Laurell, Anton Enander, Jennie Engstrand, Jacob Freedman. European Journal of Surgical Oncology. 2023 Feb;49(2):416-425.
Fulltext (DOI)
Pubmed
IV. A prospective multicentre trial on survival after Microwave Ablation VErsus Resection for Resectable Colorectal liver metastases (MAVERRIC). Pascale Tinguely, Simeon Ruiter, Jennie Engstrand, Daniel Candinas, Robbert J. de Haas, Henrik Nilsson, Koert P. de Jong, Jacob Freedman. European Journal of Cancer. 2023 Apr 5;187:65-76.
Fulltext (DOI)
Pubmed
I. Microwave ablation versus resection for colorectal cancer liver metastases - A propensity score analysis from a population-based nationwide registry. Pascale Tinguely, Gabriella Dal, Matteo Bottai, Henrik Nilsson, Jacob Freedman, Jennie Engstrand. European Journal of Surgical Oncology. 2020;46(3): 476-485.
Fulltext (DOI)
Pubmed
View record in Web of Science®
II. 3D Quantitative Ablation Margins for Prediction of Ablation Site Recurrence After Stereotactic Image-Guided Microwave Ablation of Colorectal Liver Metastases: A Multicenter Study. Simeon J. S. Ruiter / Pascale Tinguely (shared first authorship), Iwan Paolucci, Jennie Engstrand, Daniel Candinas, Stefan Weber, Robbert J. de Haas, Koert P. de Jong, Jacob Freedman. Frontiers in Oncology. 2021 Nov 15;11:757167.
Fulltext (DOI)
Pubmed
View record in Web of Science®
III. Ablation versus resection for resectable colorectal liver metastases - Healthcare-related cost and survival analyses from a quasi-randomised study. Pascale Tinguely, Gustaf Laurell, Anton Enander, Jennie Engstrand, Jacob Freedman. European Journal of Surgical Oncology. 2023 Feb;49(2):416-425.
Fulltext (DOI)
Pubmed
IV. A prospective multicentre trial on survival after Microwave Ablation VErsus Resection for Resectable Colorectal liver metastases (MAVERRIC). Pascale Tinguely, Simeon Ruiter, Jennie Engstrand, Daniel Candinas, Robbert J. de Haas, Henrik Nilsson, Koert P. de Jong, Jacob Freedman. European Journal of Cancer. 2023 Apr 5;187:65-76.
Fulltext (DOI)
Pubmed
Institution: Karolinska Institutet
Supervisor: Freedman, Jacob
Co-supervisor: Engstrand, Jennie; Nilsson, Henrik; Candinas, Daniel
Issue date: 2023-05-26
Rights:
Publication year: 2023
ISBN: 978-91-8016-900-4
Statistics
Total Visits
Views | |
---|---|
Stereostactic ... | 196 |
Total Visits Per Month
September 2023 | October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | |
---|---|---|---|---|---|---|---|
Stereostactic ... | 10 | 12 | 16 | 9 | 11 | 9 | 5 |
File Visits
Views | |
---|---|
Thesis_Pascale_Tinguely.pdf | 183 |
Top country views
Views | |
---|---|
United States | 43 |
Sweden | 25 |
Switzerland | 21 |
Germany | 14 |
South Korea | 12 |
China | 6 |
Egypt | 6 |
United Kingdom | 5 |
Israel | 4 |
Russia | 4 |
Top cities views
Views | |
---|---|
Zurich | 12 |
Cairo | 6 |
Houston | 4 |
San Mateo | 4 |
Andover | 3 |
Arezzo | 3 |
Ashburn | 3 |
Charlottesville | 3 |
Chicago | 3 |
Ammerbuch | 2 |